USRE47526E1 - Aerosolization apparatus with air inlet shield - Google Patents

Aerosolization apparatus with air inlet shield Download PDF

Info

Publication number
USRE47526E1
USRE47526E1 US14/098,403 US201314098403A USRE47526E US RE47526 E1 USRE47526 E1 US RE47526E1 US 201314098403 A US201314098403 A US 201314098403A US RE47526 E USRE47526 E US RE47526E
Authority
US
United States
Prior art keywords
capsule
pharmaceutical formulation
chamber
shield
endpiece
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/098,403
Inventor
Michael John Dunkley
Jon David Tuckwell
Edward William Vernon-Harcourt
Sameer Shirgaonkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bgp Products
BGP Products Operations GmbH
Original Assignee
Bgp Products
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US46167903P priority Critical
Priority to US10/822,850 priority patent/US7559325B2/en
Priority to US12/456,807 priority patent/US8069851B2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33299853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE47526(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bgp Products filed Critical Bgp Products
Priority to US14/098,403 priority patent/USRE47526E1/en
Assigned to BGP PRODUCTS OPERATIONS GMBH reassignment BGP PRODUCTS OPERATIONS GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS PHARMA AG
Application granted granted Critical
Publication of USRE47526E1 publication Critical patent/USRE47526E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links